NO952763L - Ekspresjonssystemer under anvendelse av autolyserende fusjonsproteiner og et nytt reduserende polypepid - Google Patents

Ekspresjonssystemer under anvendelse av autolyserende fusjonsproteiner og et nytt reduserende polypepid

Info

Publication number
NO952763L
NO952763L NO952763A NO952763A NO952763L NO 952763 L NO952763 L NO 952763L NO 952763 A NO952763 A NO 952763A NO 952763 A NO952763 A NO 952763A NO 952763 L NO952763 L NO 952763L
Authority
NO
Norway
Prior art keywords
polypepid
autolysing
fusion proteins
expression systems
novel reducing
Prior art date
Application number
NO952763A
Other languages
English (en)
Other versions
NO952763D0 (no
Inventor
Tohru Takahashi
Ryuta Koishi
Ichiro Kawashima
Nobufusa Serizawa
Original Assignee
Sankyo Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP30380994A external-priority patent/JP3337178B2/ja
Application filed by Sankyo Co filed Critical Sankyo Co
Publication of NO952763D0 publication Critical patent/NO952763D0/no
Publication of NO952763L publication Critical patent/NO952763L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0051—Oxidoreductases (1.) acting on a sulfur group of donors (1.8)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5431—IL-11
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/503—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from viruses
    • C12N9/506—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from viruses derived from RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/95—Fusion polypeptide containing a motif/fusion for degradation (ubiquitin fusions, PEST sequence)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
NO952763A 1994-07-13 1995-07-12 Ekspresjonssystemer under anvendelse av autolyserende fusjonsproteiner og et nytt reduserende polypepid NO952763L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP16105394 1994-07-13
JP21839294 1994-09-13
JP30380994A JP3337178B2 (ja) 1994-07-13 1994-12-07 クローバーイエローベインウイルスプロテアーゼ

Publications (2)

Publication Number Publication Date
NO952763D0 NO952763D0 (no) 1995-07-12
NO952763L true NO952763L (no) 1996-01-15

Family

ID=27321781

Family Applications (1)

Application Number Title Priority Date Filing Date
NO952763A NO952763L (no) 1994-07-13 1995-07-12 Ekspresjonssystemer under anvendelse av autolyserende fusjonsproteiner og et nytt reduserende polypepid

Country Status (14)

Country Link
US (3) US5955072A (no)
EP (2) EP0700999A3 (no)
KR (1) KR100417026B1 (no)
CN (4) CN1090676C (no)
AU (1) AU696358B2 (no)
CA (1) CA2153720A1 (no)
CZ (2) CZ293582B6 (no)
FI (1) FI953422A (no)
HU (2) HU0202280D0 (no)
IL (1) IL114582A0 (no)
MX (1) MX9503070A (no)
NO (1) NO952763L (no)
NZ (1) NZ272561A (no)
TW (1) TW459046B (no)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9904539D0 (sv) * 1999-12-10 1999-12-10 Alphahelix Ab Method and device for the handling of samples and reagents
FR2824334B1 (fr) * 2001-05-03 2003-10-10 Coletica Procede pour tester une substance eventuellement active dans le domaine de la lipolyse et son utilisation principalement cosmetique
EP1527175B1 (en) * 2002-06-24 2009-05-27 Exiqon A/S Methods and systems for detection and isolation of a nucleotide sequence
CN101184780B (zh) 2005-05-05 2012-10-03 森馨香料公司 β-葡聚糖和甘露聚糖的制备
EP2468881A3 (en) * 2005-07-21 2012-08-15 Abbott Laboratories Multiple gene expression including sorf contructs and methods with polyproteins, pro-proteins, and proteolysis
US20100035300A1 (en) * 2006-02-27 2010-02-11 Wang Andrew H-J Producing a Target Protein Using Intramolecular Cleavage by TEV Protease
US9206431B2 (en) * 2007-09-27 2015-12-08 Academia Sinica Kit for producing recombinant tag-cleavable fusion proteins via at least two different expression vectors allow protein production in two different species host cells
US8501449B2 (en) * 2007-12-04 2013-08-06 Proteon Therapeutics, Inc. Recombinant elastase proteins and methods of manufacturing and use thereof
JP2013509188A (ja) * 2009-10-30 2013-03-14 アボット・ラボラトリーズ Ｓｏｒｆ構築物および複数の遺伝子発現

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3885431D1 (de) * 1987-12-23 1993-12-09 Boehringer Ingelheim Int Expression der viral kodierten Protease P2A des HRV2.
US5162601A (en) * 1989-11-22 1992-11-10 The Upjohn Company Plant potyvirus expression vector with a gene for protease
US6077694A (en) * 1990-09-21 2000-06-20 The United States Of America As Represented By The Department Of Health And Human Services Method for over-expression and rapid purification of biosynthetic proteins
EP1378573A1 (en) * 1991-08-30 2004-01-07 Vertex Pharmaceuticals Incorporated Interleukin 1 beta protease and interleukin 1 beta protease inhibitors
WO1995021249A1 (en) * 1994-02-03 1995-08-10 The Scripps Research Institute A cassette to accumulate multiple proteins through synthesis of a self-processing polypeptide

Also Published As

Publication number Publication date
EP0700999A3 (en) 1997-04-16
AU696358B2 (en) 1998-09-10
KR100417026B1 (ko) 2004-05-17
AU2497095A (en) 1996-01-25
EP0700999A2 (en) 1996-03-13
US6307038B1 (en) 2001-10-23
EP1251176A3 (en) 2002-12-18
US5955072A (en) 1999-09-21
HUT72922A (en) 1996-06-28
HU9502114D0 (en) 1995-09-28
HU0202280D0 (no) 2002-09-28
CN1090676C (zh) 2002-09-11
MX9503070A (es) 1997-01-31
CN1126759A (zh) 1996-07-17
CZ293582B6 (cs) 2004-06-16
CA2153720A1 (en) 1996-01-14
NO952763D0 (no) 1995-07-12
US6743611B2 (en) 2004-06-01
CZ180895A3 (en) 1996-02-14
NZ272561A (en) 1997-03-24
CN1385529A (zh) 2002-12-18
IL114582A0 (en) 1995-11-27
CN1320689A (zh) 2001-11-07
FI953422A (fi) 1996-01-14
FI953422A0 (fi) 1995-07-13
CZ293745B6 (cs) 2004-07-14
EP1251176A2 (en) 2002-10-23
TW459046B (en) 2001-10-11
CN1385532A (zh) 2002-12-18
US20030176688A1 (en) 2003-09-18

Similar Documents

Publication Publication Date Title
NO20071415L (no) OB-fusjonsproteinpreparater og fremgangsmater
NO980255L (no) Antiparasittiske marcfortiner og paraherkvamider
NO931873D0 (no) Fremgangsmaate og system for geometrimaaling
IS1810B (is) Úðablöndur úr peptíðum og próteinum
NO961425D0 (no) 1N-alkyl-N-arylpyrimidinaminer og derivater derav
NO962333D0 (no) System og fremgangsmåte for celluloseinjeksjon
DE69637019D1 (de) Verdrehsicheres verbindungselement
DK0609841T3 (da) Optisk konnektor og klæbemiddel dertil
KR950700558A (ko) 역반사 조립체 및 그 제조방법(retroreflective assembly and process for making same)
DE69621211T2 (de) Gelenkanordnung
DE59408726D1 (de) Prothesengelenk
IT1269630B (it) Giunto omocinetico fisso
NO980566D0 (no) Allergen-XCD32 fusjonsproteiner
NO953084L (no) Fremgangsmåte og system i et fordelt driftssystem
DE69622927D1 (de) Informationsablaufverfolgungsystem und -verfahren
DE29520864U1 (de) Regenerator
NO952763D0 (no) Ekspresjonssystemer under anvendelse av autolyserende fusjonsproteiner og et nytt reduserende polypepid
FI963164A0 (fi) Diabeteksen vastaisia peptidejä ja menetelmä
DE29503122U1 (de) Sonotrode
BR9602121A (pt) Poliuretano-poliuréias e sua utilização
DE59403336D1 (de) Zapfengelenk
NO178279C (no) Skjöteanordning
FR2733287B1 (fr) Joint homocinetique
KR960010685A (ko) 펩티드 및 그 용도
PL320463A1 (en) Novel pka bonding proteins and their application

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application
FC2A Withdrawal, rejection or dismissal of laid open patent application